Allos Therapeutics, Inc. (ALTH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Allos Therapeutics, Inc. (ALTH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Mike Maxton	12/19/2009 10:31:13 AM
	Read Replies (2) of 226

[t]ALTH[/t] has been basing nicely around $6, and in my opinion, is about to move up to around $9. Analysts show an average target of $12. The company is doing all the right things in bringing this drug (FOLOTYN) to market. Revenue starts coming in January 2010. (Projected US yearly revenue of ~$300 million when fully ramped.) A partner or an outright buyout is certainly possible. I've bought 5000 shares for the Roth IRA over the last 2 months, and another 3000 shares in my trading account. I've also bought 100 January 2010 $7.5 call options at $0.10, and sold some April 7.5 puts. This stock is going up over the next year, my take is sooner rather than later. It really looks like NOW is the time to get in. mike

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next